SCHEMBL1086176

SCHEMBL1086176

Cc1cc(C)cc(CN2CC3(CCN(C(=O)c4c(-c5ccccc5Cl)noc4C)CC3)OC2=O)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPAS1 Q99814 1/20 0.56
KMT2A Q03164 4/20 0.54
LMNA P02545 6/20 0.54
ALDH1A1 P00352 5/20 0.54
HTT P42858 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
TSHR P16473 3/20 0.54
USP2 O75604 1/20 0.53
GAA P10253 2/20 0.53
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 1/20 0.50
MAPK1 P28482 1/20 0.49
RAB9A P51151 1/20 0.49
MEN1 O00255 3/20 0.49
HIF1A Q16665 1/20 0.48
GPBAR1 Q8TDU6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086265 0.94 LMNA (0.59) EPAS1KMT2ALMNAALDH1A1HTT
SCHEMBL1085863 0.82 RXFP1 (0.40) KMT2AALDH1A1HTTKDM4ERAB9A
SCHEMBL4417102 0.82 ALDH1A1 (0.44) EPAS1KMT2ALMNAALDH1A1HTT
SCHEMBL1086772 0.81 KMT2A (0.52) EPAS1KMT2ALMNAALDH1A1HTT
SCHEMBL1086278 0.81 KMT2A (0.60) KMT2ALMNASMN1; SMN2TSHRGAA
SCHEMBL1086458 0.78 KMT2A (0.56) KMT2ALMNASMN1; SMN2TSHRGAA
SCHEMBL1086721 0.78 CHRM2 (0.45) KMT2ALMNAALDH1A1KDM4EMEN1
SCHEMBL1086735 0.78 KMT2A (0.57) KMT2ALMNASMN1; SMN2TSHRGAA
SCHEMBL1086537 0.77 KMT2A (0.50) KMT2AALDH1A1TSHRUSP2NPC1
SCHEMBL1086045 0.77 KMT2A (0.54) KMT2ALMNASMN1; SMN2TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed
EP-1910381-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-04-16 EP disclosed
WO-2007000325-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC EPAS1 2866/4885KMT2A 4267/4885LMNA 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.